SNCA Rep1 microsatellite length influences non-motor symptoms in early Parkinson’s disease

Alisa CW Yong¹,*, Yi Jayne Tan¹,*, Yi Zhao², Zhonghao Lu¹, Ebonne YL Ng³, Samuel YE Ng¹, Nicole SY Chia³, Xinyi Choi³, Dede Heng³, Shermyn Neo¹, Zheyu Xu¹, Kay Yaw Tay¹, Wing Lok Au¹, Eng-King Tan³, Louis CS Tan¹,*, Adeline SL Ng¹,4, Adeline SL Ng; email: adeline.ng.s.l@singhealth.com.sg

¹Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore, Singapore
²Department of Clinical Translational Research, Singapore General Hospital, Singapore, Singapore
³Department of Neurology, National Neuroscience Institute, Singapore General Hospital, Singapore, Singapore
⁴Neuroscience and Behavioural Disorders Program, Duke-NUS Medical School, Singapore, Singapore

*Co-first authors
#Co-senior authors

Correspondence to: Adeline SL Ng; email: adeline.ng.s.l@singhealth.com.sg

Keywords: Parkinson’s disease, non-motor symptoms, SNCA, Rep1, alpha-synuclein

Received: May 7, 2020 Accepted: September 9, 2020 Published: October 20, 2020

ABSTRACT

Long alpha-synuclein gene (SNCA) promoter (Rep1) allele-carriers are linked to higher risk for Parkinson’s disease (PD) and faster motor progression. Non-motor symptoms including autonomic, neuropsychiatric, and sleep disorders are common in PD. However, the relationship between SNCA Rep1 microsatellite lengths and non-motor symptoms in early PD remains to be elucidated. 171 consecutive early PD patients were recruited from tertiary clinics and genotyped for Rep1. Multivariable regression analyses were performed to examine associations between Rep1 alleles and non-motor outcome scores. Longer Rep1 alleles significantly associated with higher total Non-Motor Symptom Scale (NMSS) scores (p=.006) and Hospital Anxiety and Depression Scale (HADS) depression subscale scores (p=.002), after adjusting for covariates and Bonferroni correction. We demonstrated that SNCA Rep1 allele length influences overall non-motor symptom burden and depression in early PD patients. Further functional studies to evaluate the role of Rep1 in non-dopaminergic systems may unravel new therapeutic targets for non-motor symptoms in PD.

INTRODUCTION

Parkinson’s disease (PD) is a clinically heterogenous neurodegenerative disorder associated with motor deficits and a spectrum of non-motor symptoms (NMS), including autonomic dysfunction, constipation, hyposmia, neuropsychiatric symptoms (cognitive impairment, depression and anxiety), and rapid eye movement (REM) sleep disorders. NMS can occur years before motor symptom onset, and are common throughout the disease [1], significantly impairing quality of life even at the earliest stages of PD [2]. To allow for risk stratification and early intervention, there remains a crucial need to identify patients at a higher risk of developing non-motor symptoms.

Pathologically, non-motor symptoms in PD have been linked to widespread alpha-synuclein (α-Syn) pathology beyond the dopaminergic nigrostriatal system [3], with α-Syn aggregates in Lewy bodies present in multiple areas of the central, autonomic and peripheral nervous systems as well as visceral organs [4]. This systemic distribution of α-Syn, along with dysfunction of extranigral neuronal populations, is suggested to be the neuropathological basis of most non-motor symptoms [5]. Furthermore, increased α-Syn pathological burden
has been found in familial PD patients possessing multiplications of the α-Syn gene (SNCA) [6]; these patients have early disease onset and rapidly progress to develop significant non-motor complications including dementia and psychiatric disturbances [7].

SNCA expression is regulated by non-amyloid component (NACP) Rep1 (GenBank DS3481), a polymorphic dinucleotide repeat sequence located ~10 kilobases upstream of the SNCA transcription start site. Rep1 functions as a negative modulator of SNCA transcription, with variation in allele length resulting in differences in the transcriptional regulation of SNCA and consequently, altered α-Syn expression [8]. Pathologically, PD carriers of the shorter genotype (259/259 base pairs [bp]) display lower levels of α-Syn in blood and post-mortem brain tissue compared to those carrying longer genotypes [9]. Expanded Rep1 alleles have also been reported in multiple cohorts to confer a higher risk for sporadic PD through increased transcription of SNCA [10–12], potentially mimicking SNCA locus multiplication [13]. A large global study found that the longer 263bp allele was associated with greater risk for PD, while the shorter 259bp allele was associated with a reduced risk for the disease [14]. Additionally, 263bp carriers have shown a four-fold increased risk of faster motor decline [15]. The strong biological link is further supported by studies that demonstrated that longer Rep1 allele carriers were more cognitively impaired [16] and at greater risk for dementia [17] than carriers of the shorter allele. No study, however, has yet investigated the relationship between Rep1 length and non-motor symptoms in PD. As non-motor symptoms usually do not occur in isolation and are not mutually exclusive, determining the association between the overall non-motor symptom burden and Rep1 may unravel new insights into the role of α-Syn in NMS pathophysiology.

To address this gap in knowledge, we investigated the relationship between Rep1 allele length and NMS in a cohort of early PD patients. We hypothesised that longer Rep1 carriers will have a greater burden of non-motor symptoms compared to short allele carriers.

RESULTS

One hundred and seventy-one early PD patients completed baseline assessments and were included in this cross-sectional study. They were stratified into short (n = 76) and long (n = 95) Rep1 carriers. Demographic and clinical features are summarized in Table 1. Mean age of the short Rep1 carrier group (63.6 ± 9.9 years) was not significantly different from the long Rep1 carrier group (64.6 ± 7.9 years) (p = .927). Disease duration and motor symptom severity also did not differ significantly between groups (disease duration – Rep1-Short: 1.07 ± 0.8 years, Rep1-Long: 1.09 ± 0.6 years, p = .334) (MDS-UPDRS Part III – Rep1-Short: 20.8 ± 7.9, Rep1-Long: 21.7 ± 10.7, p = .960). APOE4 status was available for 154 out of 171 patients. There were 31 APOE4 carriers (20.1%) and 123 non-carriers overall (Rep1-Short: 54 non-carriers (77.1%) and 16 carriers (22.9%); Rep1-Long: 69 non-carriers (82.1%) and 15 carriers (17.9%)). No significant differences were found in non-motor assessment scores in both the overall sample and within each Rep1 group between APOE4 carriers and non-carriers.

Multivariable linear regression analyses adjusted for age, sex, disease duration, MoCA score and LEDD revealed that longer Rep1 alleles were significantly associated with higher total NMSS scores (Rep1-Short: 14.3 ± 10.6, Rep1-Long: 21.0 ± 17.7, β = 6.4, p = .006), as well as with higher scores on the HADS depression subscale (Rep1-Short: 2.1 ± 1.6, Rep1-Long: 3.1 ± 2.6, β = 1.1, p = .002), and the FSS (Rep1-Short: 25.6 ± 12.6, Rep1-Long: 29.7 ± 14.1, β = 4.4, p = .032) (Table 2). After adjusting for multiple tests using Bonferroni correction, positive correlations between Rep1 allele length and total NMSS as well as HADS depression subscale scores remained significant. No patient carried pathogenic mutations in SNCA, LRRK2 (Leucine-rich repeat kinase 2), PRKN (Parkin RBR E3 Ubiquitin Protein Ligase) and PINK1 (PTEN-induced kinase 1), but there were three GBA (Glucocerebrosidase) L444P carriers. These results remained after excluding all 3 GBA L444P carriers from the analyses.

DISCUSSION

We demonstrated for the first time that SNCA Rep1 polymorphism is associated with non-motor burden in a cohort of patients at the early stages of PD as assessed by the NMSS - which includes autonomic symptoms (cardiovascular, gastrointestinal, urinary and sexual function), sleep dysfunction, fatigue, apathy, mood disorders, psychosis, sensory symptoms, and cognition. Multivariable regression analyses adjusted for age, sex, disease duration, MoCA score, LEDD, and corrected for multiple testing showed significant associations between longer Rep1 alleles and greater overall non-motor symptom burden as well as depressive symptoms, as assessed by total NMSS and HADS depression subscale scores respectively. We previously reported in a separate PD cohort with more advanced disease (mean disease duration of 5.2 years) that longer Rep1 allele PD carriers showed more cognitive and motor impairment than carriers of the shorter allele [16].

Interestingly, α-Syn has been implicated in psychiatric disorders, particularly the links between Rep1
Table 1. Demographic and clinical characteristics of PD patients.

|                          | Rep1-Short (n = 76) | Rep1-Long (n = 95) | P valueb |
|--------------------------|---------------------|-------------------|----------|
| Age, years               | 63.6 (9.9)a         | 64.6 (7.9)        | .927     |
| Sex, male                | 43 (56.5%)          | 55 (57.9%)        | .863     |
| Age at onset, years      | 62.5 (10.1)         | 63.6 (8.0)        | .968     |
| Disease duration, years  | 1.07 (0.8)          | 1.09 (0.6)        | .334     |
| MDS-UPDRS Part III: Motor| 20.8 (7.9)          | 21.7 (10.7)       | .960     |
| H&Y stage                | 1.78 (0.5)          | 1.90 (0.5)        | .030     |
| MoCA                     | 25.0 (3.3)          | 25.3 (3.8)        | .225     |
| LEDD                     | 177.8 (114.7)       | 166.7 (156.5)     | .223     |
| APOE4 carriers           | 16 (22.9%)          | 15 (17.9%)        | .546     |

**Non-Motor Assessments**

|                          | Rep1-Short (n = 76) | Rep1-Long (n = 95) | P valueb |
|--------------------------|---------------------|-------------------|----------|
| Total NMSS Score         | 14.3 (10.6)         | 21.0 (17.7)       | .020     |
| HADS Anxiety             | 2.2 (2.1)           | 2.2 (2.8)         | .397     |
| HADS Depression          | 2.1 (1.6)           | 3.1 (2.6)         | .020     |
| Apathy Scale             | 8.2 (5.5)           | 8.8 (6.6)         | .767     |
| Fatigue Severity Scale   | 25.6 (12.6)         | 29.7 (14.1)       | .067     |
| Epworth Sleepiness Scale | 5.8 (3.9)           | 6.2 (3.4)         | .563     |
| Pittsburgh Sleep Quality Index | 4.0 (3.0)    | 4.8 (3.3)         | .108     |

Abbreviation: MDS-UPDRS, Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; H&Y stage, Hoehn & Yahr stage; MoCA, Montreal Cognitive Assessment; LEDD, Levodopa Equivalent Daily Dose; NMSS, Non-Motor Symptoms Scale; HADS, Hospital Anxiety and Depression Scale.

aContinuous variables reported as mean (standard deviation); categorical variables reported as n (%)

bComparisons of variables between Rep1-Short and Rep1-Long carriers using Mann-Whitney U test for continuous variables, chi-squared test for categorical variables

cAPOE4 status was available for 154 out of 171 patients (Rep1-Short: n = 70, Rep1-Long: n = 84)

Table 2. Multivariable analysis on Rep1 status and non-motor symptoms in PD patients.

|                          | SNCA Rep1 status, long vs shortb | B (SE) | 95% CI | P valueb |
|--------------------------|----------------------------------|--------|--------|----------|
| Total NMSS Score         |                                  | 6.4 (2.3) | 1.84 – 11.04 | .006*    |
| HADS Anxiety             |                                  | 0.1 (0.4) | -0.64 – 0.87  | .766     |
| HADS Depression          |                                  | 1.1 (0.3) | 0.40 – 1.72   | .002*    |
| Apathy Scale             |                                  | 0.6 (0.9) | -1.29 – 2.43  | .544     |
| Fatigue Severity Scale   |                                  | 4.4 (2.0) | 0.39 – 8.48   | .032     |
| Epworth Sleepiness Scale |                                  | 0.3 (0.6) | -0.92 – 1.47  | .654     |
| Pittsburgh Sleep Quality Index |                  | 0.8 (0.5) | -0.12 – 1.76  | .087     |

Abbreviation: NMSS, Non-Motor Symptoms Scale; HADS, Hospital Anxiety and Depression Scale.

bMultiple linear regressions with non-motor assessment scores as outcome variables and Rep1 status as independent variable, adjusted for age, sex, disease duration, MoCA score and LEDD, B is the unstandardized beta coefficient, and SE standard error. Bolded figures indicate p < 0.05.

*Significant against Bonferroni corrected α value of p = 0.05/7 = 0.007.

Polymorphism and psychiatric symptoms. Longer Rep1 alleles were more frequent in alcohol-dependent patients compared to healthy controls [18], and correlated with greater depressive symptoms in both patients with major depressive disorder (MDD) [19] and healthy individuals [20]. Depressive symptom severity in patients with MDD also correlated with increased SNCA mRNA levels [19]. Pathological evidence of the potential role of SNCA Rep1 and/or α-Syn specifically to PD non-motor symptoms have recently been elucidated in animal models. Using a transgenic mouse model with point mutation A53T, two single nucleotide polymorphisms (SNPs) (rs11931074 (G to T) and rs3857059 (A to G)) and a Rep1 polymorphism in SNCA, Taguchi et al [21]
observed that transgenic mice exhibited hyposmia at 9 months of age, and REM sleep behaviour disorder (RBD) as early as 5 months of age. Importantly, phosphorylated α-Syn was found in brain regions seen in PD and dementia with Lewy bodies (DLB), relevant to these non-motor symptoms, such as the sublateral dorsal tegmental nucleus and olfactory bulb, consistent with the clinical findings. Additionally, mice transgenic for SNCA A53T and overexpressing α-Syn were also found to exhibit olfactory dysfunction, as well as significantly lower cholinergic neurons and decreased acetylcholinesterase activity in the olfactory bulb [22].

Evidence from neuroimaging studies also suggest involvement of neurotransmitter systems in the pathophysiology of depression in PD. Using [11C]RRI-32 as a PET marker for dopamine and noradrenaline transporter binding, reduced binding was found in the locus coeruleus and limbic regions such as the anterior cingulate cortex, thalamus, amygdala and ventral striatum amongst depressed PD patients compared to non-depressed patients [23]; the loss of dopamine and noradrenaline innervation in these brain regions also associated specifically with PD depression. Higher levels of depressive symptoms amongst PD patients also correlated with greater serotonin transporter (5-HTT) binding in the median raphe nuclei and limbic regions [24], highlighting the link between reduced serotonergic neurotransmission and PD depression.

These findings suggest the dysregulation of monoamine neurotransmitter systems in the development of depression in PD, and α-Syn has been shown to regulate dopamine, serotonin and norepinephrine transporter synaptic availability through subcellular binding, reducing the frequency of intracellular trafficking and resulting in reduced neurotransmitter levels at the cell surface [25]. Increased α-Syn levels, therefore, may lead to the dysregulation of dopaminergic, serotonergic and norepinephrine pathways [26] which mediate symptoms of mood disorders including depression [27, 28]. This is in keeping with the pathological hypothesis of depression as a result of neural system dysfunction in brain regions of the amygdala, hippocampus and prefrontal cortex, which are modulated by monoamine neurotransmitter systems [29]. Our findings that PD carriers of longer Rep1 alleles display more depressive symptoms might be explained by the modulating effect of increased SNCA expression resulting in greater dysregulation of neurotransmitter systems.

Fatigue in PD has been linked to serotonergic dysfunction within the basal ganglia and associated brain regions; PD patients with fatigue had significantly reduced serotonin transporter availability (as measured by PET ligand [11C]-DASB) in striatal and limbic regions compared to patients without fatigue, suggesting that PD fatigue is associated with reduced serotonergic function in these areas [30], providing a pathophysiological basis for the trend towards an association between Rep1 allele length and FSS scores seen in our study. However, given the fundamental difficulty in defining PD fatigue [31], elucidating its pathological basis is challenging and evidence for a serotonergic basis of PD fatigue remains limited and inconclusive.

A limitation of our study remains that individual in-depth assessments for psychosis, autonomic and sensory symptoms, were not included in the present study. These assessments will be included in future longitudinal studies.

In conclusion, our study highlights that polymorphic variation in Rep1 is associated with non-motor symptom burden, in PD patients at early stages of the disease. Further longitudinal studies to assess in more detail the effects of Rep1 on psychosis, autonomic and sensory symptoms as well as functional studies to evaluate the role of Rep1 in non-dopaminergic systems may unravel new therapeutic targets for non-motor symptoms in PD. Identifying genetic contributions to PD non-motor symptoms will aid in early identification and stratification of patients at higher risk for non-motor symptoms, which will facilitate therapeutic monitoring and understanding of PD pathophysiology.

**MATERIALS AND METHODS**

**Clinical recruitment and assessments**

Subjects were recruited under the Early Parkinson’s Disease Longitudinal Singapore Study (PALS) between 2014 and 2019. All subjects fulfilled the National Institute of Neurological Disorders and Stroke (NINDS) criteria for a diagnosis of PD [32]. PD diagnosis had to be made less than a year before recruitment, with motor symptom onset less than two years prior to diagnosis. Patients with a history of significant neurological or psychiatric conditions were excluded. No familial PD patients were included; however, there were 9 patients who reported a history of PD in a first-degree relative, and 2 patients who reported a history of PD in a second-degree relative. Ethics approval was obtained from the relevant institutional review committee, and all subjects provided informed consent.

Functional status was determined using the Hoehn & Yahr (H&Y) rating scale [33] and motor symptom severity using the Movement Disorder Society Unified

---

www.aging-us.com 20883 AGING
Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III motor component [34]. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) [35]. Where dopaminergic therapy had begun, the dosage was calculated and reported as cumulative levodopa equivalent daily dose (LEDD).

Overall non-motor symptom burden was screened for using the total score for the Non-Motor Symptoms Scale (NMSS) [36], which comprises nine domains each assessing a non-motor feature. Additionally, anxiety and depression were assessed specifically using the Hospital Anxiety and Depression Scale (HADS) [37], while levels of apathy and fatigue were evaluated via the Apathy Scale [38] and Fatigue Severity Scale (FSS) [39]. Sleep dysfunction was assessed using both the Epworth Sleepiness Scale (ESS) [40] and Pittsburgh Sleep Quality Index (PSQI) [41]. Higher scores indicate greater non-motor symptom severity and burden.

**SNCA Rep1 Polymorphism Genotyping**

Fragment length analysis of SNCA Rep1 was performed using polymerase chain reaction (PCR) according to previous methods [16]. Rep1 allele lengths were coded as described by Farrer and colleagues [10]. Subjects carrying allele lengths coded as 1 or 2 were classified as “short” carriers, while those carrying allele lengths coded as 3 were classified as “long” carriers.

**Statistical analysis**

Demographic and clinical characteristics were compared between long and short Rep1 groups using the Mann-Whitney U test for continuous variables, and chi-squared test for categorical variables. Multivariable linear regressions were performed to investigate the association between Rep1 allele length and non-motor outcomes, adjusting for statistical and clinical confounders (age, sex, disease duration, MoCA score and LEDD).

Significance level was set at $p < 0.05$, with adjustments made using Bonferroni correction for multiple testing. Statistical analysis was performed using IBM SPSS Statistics, version 21.0.

**AUTHOR CONTRIBUTIONS**

ACWY, YJT: study design, acquisition of data, data analysis and interpretation, drafting of manuscript. YZ, ZL, EYLN, SYEN, NSYC, XC, DH: acquisition of data. SN, ZX, KYT, WLA: patient recruitment. EKT: revision of manuscript for intellectual content. LCST: study design, patient recruitment, revision of manuscript for intellectual content. ASLN: study design, patient recruitment, data analysis and interpretation, revision of manuscript for intellectual content.

**ACKNOWLEDGMENTS**

The authors thank our patients and their families for their valuable contribution to the study.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**FUNDING**

This study was funded by Singapore’s National Medical Research Council (ASLN by the Clinician-Scientist New Investigator Grant (CNIG/1165/2017) and Transition Award (MOH-TA18may-0003); EKT and LCST by the Singapore Translational Research (StaR) Investigator award (NMRC/StaR/014/2013), Parkinson’s disease Translational and Clinical Research flagship grant (TCR12dec010), and Singapore PArKinson’s disease Translational Clinical Programme (SPARK, Phase II) (OH-OFLCG18May-0002)).

**REFERENCES**

1. Schapira AH, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18:435–50. https://doi.org/10.1038/nrn.2017.62 PMID:28592904

2. Duncan GW, Khoo TK, Yarnall AJ, O’Brien JT, Coleman SY, Brooks DJ, Barker RA, Burn DJ. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord. 2014; 29:195–202. https://doi.org/10.1002/mds.25664 PMID:24123307

3. Jellinger KA. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna). 2015; 122:1429–40. https://doi.org/10.1007/s00702-015-1405-5 PMID:25976432

4. Beach TG, Adler CH, Sue Li, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG, and Arizona Parkinson’s Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with lewy body disorders. Acta Neuropathol. 2010; 119:689–702. https://doi.org/10.1007/s00401-010-0664-3 PMID:20306269

5. Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson’s disease. Mov Disord. 2016; 31:1114–19. https://doi.org/10.1002/mds.26605 PMID:27030013
6. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, et al. Alpha-synuclein locus triplication causes Parkinson’s disease. Science. 2003; 302:841. https://doi.org/10.1126/science.1090278 PMID:14593171

7. Kara E, Kiely AP, Proukakis C, Giffin N, Love S, Hehir J, Rantell K, Pandraud A, Hernandez DG, Nacheva E, Pittman AM, Nalls MA, Singleton AB, et al. A 6.4 Mb duplication of the α-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations. JAMA Neurol. 2014; 71:1162–71. https://doi.org/10.1001/jama.neurol.2014.994 PMID:25003242

8. Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet. 2001; 10:3101–09. https://doi.org/10.1093/hmg/26.10.3101 PMID:11751692

9. Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, Berg D, Mueller JC, Gasser T. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008; 22:1327–34. https://doi.org/10.1096/fj.07-9348com PMID:18162487

10. Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M, West A, de Silva R, Hardy J, Hernandez D. Alpha-synuclein gene haplotypes are associated with Parkinson’s disease. Hum Mol Genet. 2001; 10:1847–51. https://doi.org/10.1093/hmg/10.17.1847 PMID:11532993

11. Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, Van den Broeck M, De Pooter T, Cras P, Crook J, Van Broeckhoven C, Farrer MJ. Alpha-synuclein promoter confers susceptibility to Parkinson’s disease. Ann Neurol. 2004; 56:591–95. https://doi.org/10.1002/ana.20268 PMID:15455394

12. Tan EK, Chai A, Teo YY, Zhao Y, Tan C, Shen H, Chandran VR, Teoh ML, Yih Y, Pavanri R, Wong MC, Puvan K, Lo YL, Yap E. Alpha-synuclein haplotypes implicated in risk of Parkinson’s disease. Neurology. 2004; 62:128–31. https://doi.org/10.1212/01.wnl.0000101721.25345.dc PMID:14718715

13. Cronin KD, Ge D, Manning P, Linnertz C, Rossoshek A, Orrison BM, Bernard DJ, El-Agnaf OM, Schlossmacher MG, Nussbaum RL, Chiba-Falek O. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet. 2009; 18:3274–85. https://doi.org/10.1093/hmg/ddp265 PMID:19498036

14. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, Roca WA, Schneider NK, Lesnick TG, Lincoln SJ, Hulihan MM, Aasly JO, Ashizawa T, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA. 2006; 296:661–70. https://doi.org/10.1001/jama.296.6.661 PMID:16896109

15. Ritz B, Rhodes SL, Bordeloy Y, Bronstein J. A-synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One. 2012; 7:e36199. https://doi.org/10.1371/journal.pone.0036199 PMID:22615757

16. Ng AS, Tan YJ, Zhao Y, Saffari SE, Lu Z, Ng EY, Ng SY, Chia NS, Setiawan F, Xu Z, Tay KY, Au WL, Tan LC, Tan EK. SNCA Rep1 promoter variability influences cognition in Parkinson’s disease. Mov Disord. 2019; 34:1232–36. https://doi.org/10.1002/mds.27768 PMID:31234238

17. Corrado L, De Marchi F, Tunesi S, Oggoni GD, Careccio M, Magistrelli L, Tesei S, Riboldazzi G, Di Fonzo A, Locci C, Trezzi I, Zangaglia R, Cereda C, et al. The length of SNCA Rep1 microsatellite may influence cognitive evolution in Parkinson’s disease. Front Neurol. 2018; 9:213. https://doi.org/10.3389/fneur.2018.00213 PMID:29662465

18. Bönisch D, Lederer T, Reulbach U, Hothorn T, Kornhuber J, Bleich S. Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence. Hum Mol Genet. 2005; 14:967–71. https://doi.org/10.1093/hmg/ddi090 PMID:15731118

19. Rotter A, Lenz B, Pitsch R, Richter-Schmidinger T, Kornhuber J, Rhein C. Alpha-synuclein RNA expression is increased in major depression. Int J Mol Sci. 2019; 20:2029. https://doi.org/10.3390/ijms20082029 PMID:31027150

20. Lenz B, Sysk C, Thuerauf N, Clepce M, Reich K, Frieling H, Winterger S, Bleich S, Kornhuber J. NACP-Rep1 relates to beck depression inventory scores in healthy humans. J Mol Neurosci. 2011; 44:41–47. https://doi.org/10.1007/s12031-011-9493-7 PMID:21271299

21. Taguchi T, Ikuno M, Hondo M, Parajuli LK, Taguchi K, Ueda J, Sawamura M, Okuda S, Nakanishi E, Hara J, Uemura N, Hatanaka Y, Ayaki T, et al. A-synuclein BAC
22. Zhang S, Xiao Q, Le W. Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein. PLoS One. 2015; 10:e0119928. 
https://doi.org/10.1371/journal.pone.0119928
PMID: 25799501

23. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005; 128:1314–22. 
https://doi.org/10.1093/brain/awh445
PMID: 15716302

24. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010; 75:1920–27. 
https://doi.org/10.1212/WNL.0b013e3181feb2ab
PMID: 21098407

25. Wersinger C, Rusnak M, Sidhu A. Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein. Eur J Neurosci. 2006; 24:55–64. 
https://doi.org/10.1111/j.1460-9568.2006.04900.x
PMID: 16882006

26. Oaks AW, Sidhu A. Synuclein modulation of monoamine transporters. FEBS Lett. 2011; 585:1001–06. 
https://doi.org/10.1016/j.febslet.2011.03.009
PMID: 21396366

27. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000 (Suppl 1); 12:2–19. 
https://doi.org/10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4
PMID: 11098410

28. Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease—epidemiology, mechanisms and management. Nat Rev Neurol. 2011; 8:35–47. 
https://doi.org/10.1038/nrneurol.2011.189
PMID: 22198405

29. Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry. 2000 (Suppl 1); 61:5–12. 
PMID: 10703757

30. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain. 2010; 133:3434–43. 
https://doi.org/10.1093/brain/awq268
PMID: 20884645

31. Friedman JH, Beck JC, Chou KL, Clark G, Fagundes CP, Goetz CG, Herlofson K, Kluger B, Krupp LB, Lang AE, Lou JS, Marsh L, Newbould A, Weintraub D. Fatigue in Parkinson’s disease: report from a multidisciplinary symposium. NPJ Parkinsons Dis. 2016; 2:15025. 
https://doi.org/10.1038/njpjparkd.2015.25
PMID: 27239558

32. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56:33–39. 
https://doi.org/10.1001/archneur.56.1.33
PMID: 9923759

33. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967; 17:427–42. 
https://doi.org/10.1212/wnl.17.5.427
PMID: 6067254

34. Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord. 2003; 18:738–50. 
https://doi.org/10.1002/mds.10473
PMID: 12815652

35. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53:695–99. 
https://doi.org/10.1111/j.1532-5415.2005.53221.x
PMID: 15817019

36. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007; 22:1901–11. 
https://doi.org/10.1002/mds.21596
PMID: 17674410

37. Snaitl RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003; 1:29. 
https://doi.org/10.1186/1477-7525-1-29
PMID: 12914662

38. Starksen SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992; 4:134–39. 
https://doi.org/10.1176/jnp.4.2.134
PMID: 1627973

39. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46:1121–23.
40. Johns MW. A new method for measuring daytime sleepiness: the epworth sleepiness scale. Sleep. 1991; 14:540–45. 
https://doi.org/10.1093/sleep/14.6.540
PMID: 1798888

41. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28:193–213. 
https://doi.org/10.1016/0165-1781(89)90047-4
PMID: 2748771